The American College of Obstetricians and Gynecologists (The College) and the Society for Maternal-Fetal Medicine (SMFM) have recommended Chromosomal Microarray Analysis (CMA) as the first-line genetic test in pregnancies showing fetal abnormalities in an ultrasound scan.
CMA is capable of detecting smaller genetic anomalies which are not detected by standard Karyotyping analysis. Moreover, CMA is a computerized test and hence more reliable as compared to Karyotyping which is dependent on manual process and skills.
|Recommendations:The College and the Society for Maternal-Fetal Medicine offer the following recommendations for the use of chromosomal microarray analysis in prenatal diagnosis.
Committee Opinion #581 “The Use of Chromosomal Microarray Analysis in Prenatal Diagnosis” is published in the December issue of Obstetrics & Gynecology.